Apellis Pharmaceuticals - APLS Stock Forecast, Price & News

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Apellis Pharmaceuticals in the last year. There are currently 1 sell rating, 2 hold ratings, 9 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" APLS shares.
View APLS analyst ratings or view top-rated stocks.

13 analysts have issued 1 year price targets for Apellis Pharmaceuticals' stock. Their APLS share price forecasts range from $40.00 to $113.00. On average, they predict the company's share price to reach $76.23 in the next year. This suggests a possible upside of 26.5% from the stock's current price.
View analysts price targets for APLS or view top-rated stocks among Wall Street analysts.

Apellis Pharmaceuticals' stock was trading at $47.28 at the start of the year. Since then, APLS shares have increased by 27.5% and is now trading at $60.26.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our APLS earnings forecast.

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) issued its earnings results on Monday, August, 8th. The company reported ($1.46) EPS for the quarter, missing the consensus estimate of ($1.43) by $0.03. The firm earned $16.32 million during the quarter, compared to the consensus estimate of $17.16 million. Apellis Pharmaceuticals had a negative net margin of 660.59% and a negative trailing twelve-month return on equity of 272.25%. During the same period in the previous year, the business posted ($2.72) EPS.

18 employees have rated Apellis Pharmaceuticals Chief Executive Officer Cedric Francois on Glassdoor.com. Cedric Francois has an approval rating of 100% among the company's employees. This puts Cedric Francois in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 74.0% of employees surveyed would recommend working at Apellis Pharmaceuticals to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Apellis Pharmaceuticals investors own include AbbVie (ABBV), OPKO Health (OPK), Fate Therapeutics (FATE), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), Amarin (AMRN), Anavex Life Sciences (AVXL), Axsome Therapeutics (AXSM) and BioXcel Therapeutics (BTAI).

(APLS) raised $150 million in an initial public offering (IPO) on Thursday, November 9th 2017. The company issued 10,700,000 shares at $13.00-$15.00 per share. Citigroup, J.P. Morgan and Evercore ISI served as the underwriters for the IPO.

Apellis Pharmaceuticals trades on the NASDAQ under the ticker symbol "APLS."

Shares of APLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of APLS stock can currently be purchased for approximately $60.26.

Apellis Pharmaceuticals (NASDAQ:APLS) has a market capitalization of $6.62 billion and generates $66.56 million in revenue each year. The company earns $-746,350,000.00 in net income (profit) each year or ($6.77) on an earnings per share basis.

The company employs 476 workers across the globe.

Apellis Pharmaceuticals' mailing address is 100 FIFTH AVENUE, WALTHAM MA, 02451. The official website for the company is www.apellis.com. The company can be reached via phone at (617) 977-5700 or via email at investors@apellis.com.